The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000483358
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
2/04/2026
Date registered
Help: Date registered
17/04/2026
Date last updated
Help: Date last updated
31/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
17/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Phase 1 Study of CLIP-100 in Healthy Adults
Scientific title
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous CLIP-100 in Healthy Adults
Additional trial identifiers [1] 316921 0
AB-25-001
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Localized Subcutaneous Fat (Abdominal) 341341 0
Condition category
Condition code
Skin 337410 337410 0 0
Other skin conditions

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a dose-escalation study evaluating single ascending dose cohorts of CLIP-100 (30mg, 60mg, 120mg, 240mg, 300mg). A single dose will be administered by subcutaneous injection into the abdominal adipose tissue by clinical staff at the Phase 1 facility under direct medical supervision. Progression to each subsequent cohort requires review of available safety, tolerability and PK data through at least Day 8 by the Safety Monitoring Committee. Adherence is confirmed by direct observation of injection administration and documentation at the Phase 1 facility. PK sampling throughout the study period provides objective confirmation of drug exposure.
Intervention code [1] 333636 0
Treatment: Drugs
Description of the comparator or control
0.9% Sodium Chloride
Control group
Placebo

Outcomes
Primary outcome [1] 344937 0
Safety
Timepoint [1] 344937 0
Monitored and assessed throughout the study (Screening, Day 1/dose administration, Day 2, 3, 4, 8, 15, 22, and 29). Day 22 and 29 was added after enrolment of 8 participants.
Primary outcome [2] 345046 0
Tolerability
Timepoint [2] 345046 0
Pose-dose Day 1 through Day 29. Additional time from Day 15 to Day 29 was added after enrollment of 8 participants and impacts Cohorts 1-4.
Secondary outcome [1] 459864 0
Characterize the pharmacokinetics of CLIP-100 (study drug)
Timepoint [1] 459864 0
Blood samples collected pre-dose and at 1, 2, 4, 8, and 12 hours post-dose on Day 1; 24 hours post-dose (Day 2); 48 hours post-dose (Day 3, initial cohorts only); 72 hours post-dose (Day 4); 168 hours post-dose (Day 8); and 336 hours post-dose (Day 15)

Eligibility
Key inclusion criteria
1. Participant must be 18 to 64 years of age inclusive, at the time of signing the informed consent
2. Participants who are overtly healthy as determined by medical evaluations including medical history, physician examination, vital signs, laboratory tests and cardiac monitoring.
3. Body weight greater than or equal to 50 kg at screening and Day -1 and a body mass index (BMI) within the range, greater than 18.5 and less than 32 kg/m².
Minimum age
18 Years
Maximum age
64 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
1. Clinically significant history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, haematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the trial intervention; or interfering with the data
2. Abnormal skin or local skin condition in the abdominal region
3. Current or chronic history of liver disease.
4. On prescription or over the counter (OTC) weight reduction medication, weight reduction programs, or taking oral/injectable GLP-1 agonists
5. Unable to receive local anaesthesia or hypersensitivity to lidocaine.
6. Current enrolment or past participation in another investigational trial in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered withing 90 days before signing consent in this clinical trial
7. Participants with fever or any acute infection within 28 days of screening and throughout Day 1
8. Previous surgery which caused scarring in the abdominal region
9. Prior history of any aesthetic procedures to the abdominal region, including liposuction, tattoos, injectable products, poly-l-lactic acid, etc.
10. Presence of metallic implants, pacemakers, neurostimulators, cochlear implants, or other MRI-incompatible devices or materials, or severe claustrophobia that would prevent completion of an MRI scan (applies to participants enrolled in Cohorts 2, 3, and 4).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation concealment is maintained through the use of sealed opaque envelopes containing the pre-generated randomization schedule prepared by the sponsor's designee prior to the trial. Eligible participants are assigned a unique randomization number on Day 1, and the corresponding sealed envelope is opened at the time of dispensing. Trial intervention is dispensed in blinded packaging labelled only with the participant's randomization number. The enrolling investigator is not aware of the intervention assignment at the time of eligibility determination
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomized 3:1 to CLIP-100 to Placebo according to a randomization schedule. Simple randomization using a randomization table created by computer software.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29356 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 45673 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 321516 0
Commercial sector/Industry
Name [1] 321516 0
Amalfi Bio, Inc
Country [1] 321516 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Amalfi Bio, Inc
Address
Country
United States of America
Secondary sponsor category [1] 324401 0
None
Name [1] 324401 0
Address [1] 324401 0
Country [1] 324401 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320050 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320050 0
Ethics committee country [1] 320050 0
Australia
Date submitted for ethics approval [1] 320050 0
24/02/2026
Approval date [1] 320050 0
31/03/2026
Ethics approval number [1] 320050 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149266 0
Dr Aarthy Joseph
Address 149266 0
Nucleus Network, Level 5, Burnet Tower, 89 Commercial Road, Melbourne, VIC 3004
Country 149266 0
Australia
Phone 149266 0
+61 03 8593 9801
Fax 149266 0
Email 149266 0
Contact person for public queries
Name 149267 0
Courtney Maguire
Address 149267 0
Amalfi Bio, 1301 Riverplace Blvd, Suite 800, Jacksonville, FL 32297
Country 149267 0
United States of America
Phone 149267 0
+1 904 736 7271
Fax 149267 0
Email 149267 0
Contact person for scientific queries
Name 149268 0
Courtney Maguire
Address 149268 0
Amalfi Bio, 1301 Riverplace Blvd, Suite 800, Jacksonville, FL 32297
Country 149268 0
United States of America
Phone 149268 0
+1 904 736 7271
Fax 149268 0
Email 149268 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.